VITAMIN E IN TREATMENT OF IGA NEPHROPATHY IN CHILDREN

维生素 E 治疗儿童 IGA 肾病

• 批准号: 6263689
• 负责人: JOSEPH T FLYNN
• 金额: $ 0.02万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6263689
• 关键词: IgA nephropathy; blood chemistry; child (0-11); clinical research; clinical trials; human subject; longitudinal human study; nutrition related tag; tocopherols; urinalysis; vitamin therapy; young adult human (21-34)

At present, there is no treatment for IgA Nephropathy that has been proven to be clinically effective. This is a multicenter study in which children and young adults with biopsy-proven, clinically mild IgA Nephropathy will be randomized to receive either Vitamin E or placebo daily. After baseline laboratory data has been obtained and the subject has been randomized, they will be seen in follow-up every four months for a period of two years. Blood and urine samples will be obtained at these visits, and a 48 hour urine collection will be obtained annually. Risk of participation in the study is minimal, as there are no harmful effects of Vitamin E at the doses to be used in the study. The benefit to participation is possible amelioration of IgA Nephropathy in Vitamin E recipients if the treatment is effective; there is no direct benefit to placebo recipients. It is hoped that the results of this study will lead to an effective treatment for IgA Nephropathy.

目前，尚无对IgA肾病的治疗方法，事实证明是临床上有效的。 这是一项多中心研究，其中有活检，临床温和的IgA肾病的儿童和年轻人每天都会随机接受维生素E或安慰剂。 在获得基线实验室数据并且对受试者进行了随机分析后，每四个月的随访中，在两年内都会看到它们。这些访问将获得血液和尿液样本，每年将获得48小时的尿液。 参与研究的风险很小，因为在研究中使用的剂量没有维生素E的有害作用。 参与的好处是如果治疗有效，可以改善维生素E的IgA肾病。安慰剂接受者没有直接的好处。 希望这项研究的结果将导致对IgA肾病的有效治疗。